Literature DB >> 9521145

Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis.

G Hetland1, H G Wiker, K Høgåsen, B Hamasur, S B Svenson, M Harboe.   

Abstract

We examined alternative and classical complement activation induced by whole bacilli of Mycobacterium bovis BCG and Mycobacterium tuberculosis products. After exposure to BCG, there were higher levels of the terminal complement complex in sera from Indian tuberculosis patients than in sera from healthy controls. The addition of BCG with or without EGTA to these sera indicated that approximately 70 to 85% of the total levels of the terminal complement complex was formed by classical activation. Sera from Indian tuberculosis patients contained more antibody to lipoarabinomannan (LAM) than sera from healthy Indians. Levels of anti-LAM immunoglobulin G2 (IgG2), but not anti-LAM IgM, correlated positively with classical activation induced by BCG in the sera. By flow cytometry, deposition of C3 and terminal complement complex on bacilli incubated with normal human serum was demonstrated. The anticomplement staining was significantly reduced in the presence of EGTA and EDTA. Flow cytometry also revealed the binding of complement to BCG incubated with rabbit anti-LAM and then with factor B-depleted serum. This indicates that classical activation plays a major role in complement activation induced by mycobacteria and that anti-LAM IgG on the bacilli can mediate this response. Classical complement activation may be important for the extent of phagocytosis of M. tuberculosis by mononuclear phagocytes, which may influence the course after infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521145      PMCID: PMC121360          DOI: 10.1128/CDLI.5.2.211-218.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  33 in total

1.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.

Authors: 
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3.

Authors:  L S Schlesinger; C G Bellinger-Kawahara; N R Payne; M A Horwitz
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

3.  Heterogenous expression of the related MPB70 and MPB83 proteins distinguish various substrains of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv.

Authors:  H G Wiker; S Nagai; R G Hewinson; W P Russell; M Harboe
Journal:  Scand J Immunol       Date:  1996-04       Impact factor: 3.487

4.  Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages.

Authors:  C D Gaynor; F X McCormack; D R Voelker; S E McGowan; L S Schlesinger
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

5.  Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?

Authors:  A M Costello; A Kumar; V Narayan; M S Akbar; S Ahmed; C Abou-Zeid; G A Rook; J Stanford; C Moreno
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

6.  Serum lectin with known structure activates complement through the classical pathway.

Authors:  K Ikeda; T Sannoh; N Kawasaki; T Kawasaki; I Yamashina
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

7.  Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3.

Authors:  P Garred; T E Mollnes; T Lea
Journal:  Scand J Immunol       Date:  1988-03       Impact factor: 3.487

8.  Lipoarabinomannan inhibits nonopsonic binding of Mycobacterium tuberculosis to murine macrophages.

Authors:  R W Stokes; D P Speert
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

9.  Increased frequency of homozygosity of abnormal mannan-binding-protein alleles in patients with suspected immunodeficiency.

Authors:  P Garred; H O Madsen; B Hofmann; A Svejgaard
Journal:  Lancet       Date:  1995-10-07       Impact factor: 79.321

10.  The human mannose-binding protein functions as an opsonin.

Authors:  M Kuhlman; K Joiner; R A Ezekowitz
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  17 in total

1.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Specific and randomly derived immunoactive peptide mimotopes of mycobacterial antigens.

Authors:  Archna Sharma; Abhik Saha; Surajit Bhattacharjee; Subrata Majumdar; Sujoy K Das Gupta
Journal:  Clin Vaccine Immunol       Date:  2006-08-17

3.  Effect of mycobacterial phospholipids on interaction of Mycobacterium tuberculosis with macrophages.

Authors:  L M Thorson; D Doxsee; M G Scott; P Wheeler; R W Stokes
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 4.  B cells and antibodies in the defense against Mycobacterium tuberculosis infection.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

5.  Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.

Authors:  A Glatman-Freedman; A J Mednick; N Lendvai; A Casadevall
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

Review 6.  Antibody-mediated immunity against tuberculosis: implications for vaccine development.

Authors:  Jacqueline M Achkar; Arturo Casadevall
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

7.  Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.

Authors:  J Scott Ferguson; Jeremy J Weis; Jennifer L Martin; Larry S Schlesinger
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis.

Authors:  B Hamasur; M Haile; A Pawlowski; U Schroder; G Kallenius; S B Svenson
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

9.  Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci.

Authors:  Q Chang; Z Zhong; A Lees; M Pekna; L Pirofski
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 10.  Role of B cells and antibodies in acquired immunity against Mycobacterium tuberculosis.

Authors:  Jacqueline M Achkar; John Chan; Arturo Casadevall
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-09       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.